Sign Up Today and Learn More About Atsena Therapeutics Stock
Invest in or calculate the value of your shares in Atsena Therapeutics or other pre-IPO companies through EquityZen's platform.
Atsena Therapeutics Stock
Atsena Therapeutics is a clinical-stage gene therapy company that develops novel treatments for inherited forms of blindness.
About Atsena Therapeutics Stock
Founded
2019
Headquarters
Durham, NC, US
Industries
Software, Artificial Intelligence, Data and Analytics
Atsena Therapeutics Press Mentions
Stay in the know about the latest news on Atsena Therapeutics
Innovation in ophthalmology: How biotechs are reshaping the treatment of eye diseases
labiotech • Feb 19, 2026
Genezen and Atsena Therapeutics Announce Strategic Commercial Manufacturing Partnership
prnewswire • Jan 20, 2026
Atsena Completes Dosing in Part B of the Phase I/II/III LIGHTHOUSE Trial Evaluating ATSN-201 to Treat X-linked Retinoschisis and Announces Plans for Initiation of Pivotal Part C Cohort
globenewswire • Jan 09, 2026
Atsena Therapeutics Appoints McDavid Stilwell as Chief Financial Officer
globenewswire • Jan 06, 2026
Lightstone Ventures Marks Year-to-Date 2025 Milestones for its Innovative Biotech and Medtech Portfolio Companies
citybiz • Sep 25, 2025
Atsena Therapeutics Management
Leadership team at Atsena Therapeutics
Founder and Chief Technology Officer
Sanford Boye
Advisor
Sarah Bhagat
Join now and verify your accreditation status to gain access to:
- Atsena Therapeutics Current Valuation
- Atsena Therapeutics Stock Price
- Atsena Therapeutics Management
- Available deals in Atsena Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Atsena Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Atsena Therapeutics Revenue and Financials
- Atsena Therapeutics Highlights
- Atsena Therapeutics Business Model
- Atsena Therapeutics Risk Factors
- Atsena Therapeutics Research Report from SACRA Research
Trading Atsena Therapeutics Stock
How to invest in Atsena Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Atsena Therapeutics through EquityZen funds. These investments are made available by existing Atsena Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Atsena Therapeutics stock?
Shareholders can sell their Atsena Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 430K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 51K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."